Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Dosing Model Based on Anti-tuberculosis Drug Monitoring NAT2 Genotypes in Tuberculosis Patients.

NCT02747654 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02747654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02747654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Dosing Model Based on Anti-tuberculosis Drug Monitoring NAT2 Genotypes in Tuberculosis Patients.
Lead sponsor
Samsung Medical Center
Phase
Not applicable
Overall status
Unknown status
Start date
June 30, 2014
Completion date
Not reported
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nat2 genotype